Rigel Pharmaceuticals (RIGL -9.5%) drops after a hard miss on its Q4 EPS. Operating expenses...


Rigel Pharmaceuticals (RIGL -9.5%) drops after a hard miss on its Q4 EPS. Operating expenses soared 25% Y/Y, primarily due to the increase in R&D expenses related to R343, its inhaled inhibitor program for asthma, and R333, its topical inhibitor program for lupus.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs